Nasdaq-listed Prothena, a late-stage clinical biotechnology company, has priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of US$56.50 per share. All…
Nasdaq-listed Prothena, a late-stage clinical biotechnology company, has priced an underwritten public offering of 3,250,000 of its ordinary shares at a price to the public of US$56.50 per share. All…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference